This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Use of cystatin C for chronic kidney disease evaluation and sodium–glucose cotransporter-2 inhibitors as first-line therapy are among the changes put forth by KDIGO.
Medscape Medical News